Undisclosed dual payload ADC 1

Undisclosed dual payload ADC 1 refers to an experimental Antibody-Drug Conjugate (ADC) that incorporates two distinct therapeutic payloads attached to a monoclonal antibody. ADCs are a class of targeted biotherapeutics designed to combine the tumor-targeting specificity of monoclonal antibodies with the potent cytotoxic activity of chemotherapeutic agents. The concept behind dual-payload ADCs is to enhance therapeutic efficacy through synergistic effects of the two payloads, overcome tumor heterogeneity and drug resistance, and potentially reduce systemic toxicity by precisely delivering the cytotoxic agents directly to cancer cells. While the specific antibody target, payloads, and linker for this particular 'Undisclosed dual payload ADC 1' are not publicly known, dual-payload ADCs generally aim to target various biological pathways or multiple nodes within the same pathway, leading to improved anti-tumor responses compared to single-payload ADCs.